Basal cell carcinoma - Symptoms, Causes, Images, and Treatment Options

Diseases

Highlights & Basics

Key Highlights

Basal cell carcinoma (BCC) clinically presents as a pearly white/pink papulo-nodule or firm plaque.
Patient usually has prominent solar damage or a history of considerable ultraviolet (UV) radiation exposure.
Can be locally aggressive, but rarely metastasizes.
Diagnosis of a cancer is histologic. Findings are of dermal masses of varying sizes and shapes composed of basophilic cells with large oval rather uniform nuclei and scant cytoplasm. These masses exhibit a peripheral cell layer demonstrating a palisading pattern of nuclei.
Most BCCs are successfully treated with surgery, with low recurrence rates.

Nodular basal cell carcinoma on the cheek, on background of diffuse solar damage with marked solar elastosis

From the collection of Prof. Robert A. Schwartz

Quick Reference

History & Exam
- Key Factors
- Other Factors
More information...
Diagnostics Tests
More information...
Treatment Options
More information...

Definition

Epidemiology

Etiology

Pathophysiology

Images

Nodular basal cell carcinoma on the cheek, on background of diffuse solar damage with marked solar elastosis
Superficial BCC: A plaque somewhat translucent with focal crusting and ulceration, enlarging with a nodular quality
Digital dermoscopy image of above superficial basal cell carcinoma utilizing Sklip PRO dermatoscope
Histologic appearance of basal cell carcinoma (20x, H-E stain); characteristic peripheral nuclear palisading, stroma-epithelium split, and so-called mucinous nature of the stroma are seen

Citations

Key Articles

Nasr I, McGrath EJ, Harwood CA, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021. Br J Dermatol. 2021 Nov;185(5):899-920.[Abstract][Full Text]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: basal cell skin cancer [internet publication].[Full Text]
Kim JYS, Kozlow JH, Mittal B, et al; Work Group, Invited Reviewers. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):540-59.[Abstract][Full Text]
Thomson J, Hogan S, Leonardi-Bee J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020 Nov 17;(11):CD003412.[Abstract][Full Text]

Other Online Resources

CRUK: cancer incidence statistics

Referenced Articles

1. Iannacone MR, Wang W, Stockwell HG, et al. Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin - a case-control study. BMC Cancer. 2012 Sep 20;12:417.[Abstract][Full Text]
2. Bauer A, Diepgen TL, Schmitt J. Is occupational solar ultraviolet irradiation a relevant risk factor for basal cell carcinoma? A systematic review and meta-analysis of the epidemiological literature. Br J Dermatol. 2011 Sep;165(3):612-25.[Abstract]
3. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol. 2006 Aug;155(2):401-7.[Abstract]
4. Lear W, Dahlke E, Murray CA. Basal cell carcinoma: review of epidemiology, pathogenesis, and associated risk factors. J Cutan Med Surg. 2007 Jan-Feb;11(1):19-30.[Abstract]
5. Barnhill RL, ed. Textbook of dermatopathology, 2nd ed. New York: McGraw-Hill Medical; 2004.
6. Kauvar AN, Cronin T Jr, Roenigk R, et al. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg. 2015 May;41(5):550-71.[Abstract]
7. LeBoit PE. Stroma, interrupted. Am J Dermatopathology. 2001 Feb;23(1):67-8.[Abstract]
8. Betti R, Menni S, Radaelli G, et al. Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol. 2010 Jul;37(7):611-6.[Abstract]
9. Skroza N, Panetta C, Schwartz RA, et al. Giant meta-typical carcinoma: an unusual tumor. Acta Dermatovenerol Croat. 2006;14(1):46-51.[Abstract]
10. The College of Optometrists. Clinical management guidelines: basal cell carcinoma (BCC) (periocular). Apr 2022 [internet publication].[Full Text]
11. Ionescu DN, Arida M, Jukic DM. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med. 2006 Jan;130(1):45-51.[Abstract]
12. Hu W, Fang L, Ni R, et al. Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years. BMC Cancer. 2022 Jul 30;22(1):836.[Abstract][Full Text]
13. Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014 May-Jun;24(3):312-29.[Abstract]
14. Maybury CM, Craythorne E, Martin B. An ulcerated nodule on the nose. BMJ Case Rep. 2013 Apr 16;2013:bcr2012008296.[Abstract][Full Text]
15. Ciążyńska M, Kamińska-Winciorek G, Lange D, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021 Feb 22;11(1):4337.[Abstract][Full Text]
16. Rogers HW, Weinstock MA, Feldman SR, et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015 Oct;151(10):1081-6.[Abstract][Full Text]
17. Xiang F, Lucas R, Hales S, et al. Incidence of nonmelanoma skin cancer in relation to ambient UV radiation in white populations, 1978-2012: empirical relationships. JAMA Dermatol. 2014 Oct;150(10):1063-71.[Abstract][Full Text]
18. Reifenberger J. Basal cell carcinoma: molecular genetics and unusual clinical features. Hautarzt. 2007 May;58(5):406-11.[Abstract]
19. Balk SJ; Council on Environmental Health; Section on Dermatology. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics. 2011 Mar;127(3):e791-817.[Abstract][Full Text]
20. Youssef KK, Van Keymeulen A, Lapouge G, et al. Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol. 2010 Mar;12(3):299-305.[Abstract]
21. de Zwaan SE, Haass NK. Genetics of basal cell carcinoma. Australas J Dermatol. 2010 May;51(2):81-92; quiz 93-4.[Abstract]
22. Morgan H, Olivero C, Patel GK. Identification of human cutaneous basal cell carcinoma cancer stem cells. Methods Mol Biol. 2019;1879:435-50.[Abstract]
23. Milosevic M, Lazarevic M, Toljic B, et al. Characterization of stem-like cancer cells in basal cell carcinoma and its surgical margins. Exp Dermatol. 2018 Oct;27(10):1160-5.[Abstract]
24. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9.[Abstract]
25. Marin-Gutzke M, Sanchez-Olaso A, Berenguer B, et al. Basal cell carcinoma in childhood after radiation therapy: case report and review. Ann Plast Surg. 2004 Dec;53(6):593-5.[Abstract]
26. Karagas MR, Gossai A, Pierce B, et al. Drinking water arsenic contamination, skin lesions, and malignancies: a systematic review of the global evidence. Curr Environ Health Rep. 2015 Mar;2(1):52-68.[Abstract][Full Text]
27. Yu HS, Liao WT, Chai CY. Arsenic carcinogenesis in the skin. J Biomed Sci. 2006 Sep;13(5):657-66.[Abstract]
28. Rossy KM, Janusz CA, Schwartz RA. Cryptic exposure to arsenic. Indian J Dermatol Venereol Leprol. 2005 Jul-Aug;71(4):230-5.[Abstract][Full Text]
29. Kilgour JM, Jia JL, Sarin KY. Review of the molecular genetics of basal cell carcinoma; inherited susceptibility, somatic mutations, and targeted therapeutics. Cancers (Basel). 2021 Jul 31;13(15):3870.[Abstract][Full Text]
30. Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016 Apr;48(4):398-406.[Abstract]
31. Lambert WC, Lambert MW. Development of effective skin cancer treatment and prevention in xeroderma pigmentosum. Photochem Photobiol. 2015 Mar-Apr;91(2):475-83.[Abstract][Full Text]
32. Bresler SC, Padwa BL, Granter SR. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Head Neck Pathol. 2016 Jun;10(2):119-24.[Abstract][Full Text]
33. Evans DG, Farndon PA. Nevoid basal cell carcinoma syndrome. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Mar 2018 [internet publication].[Full Text]
34. Boonen SE, Stahl D, Kreiborg S, et al. Delineation of an interstitial 9q22 deletion in basal cell nevus syndrome. Am J Med Genet A. 2005 Jan 30;132A(3):324-8.[Abstract]
35. de Meij TG, Baars MJ, Gille JJ, et al. From gene to disease: basal cell naevus syndrome. Ned Tijdschr Geneeskd. 2005 Jan 8;149(2):78-81.[Abstract]
36. Pastorino L, Cusano R, Nasti S, et al. Molecular characterization of Italian nevoid basal cell carcinoma syndrome patients. Hum Mutat. 2005 Mar;25(3):322-3.[Abstract]
37. Ragge NK, Salt A, Collin JR, et al. Gorlin syndrome: the PTCH gene links ocular developmental defects and tumour formation. Br J Ophthalmol. 2005 Aug;89(8):988-91.[Abstract]
38. John AM, Schwartz RA. Basal cell naevus syndrome: an update on genetics and treatment. Br J Dermatol. 2016 Jan;174(1):68-76.[Abstract]
39. Teepen JC, Kok JL, Kremer LC, et al; DCOG-LATER Study Group. Long-term risk of skin cancer among childhood cancer survivors: a DCOG-LATER cohort study. J Natl Cancer Inst. 2019 Aug 1;111(8):845-53.[Abstract][Full Text]
40. Kanitakis J, Alhaj-Ibrahim L, Euvrard S, et al. Basal cell carcinomas developing in solid organ transplant recipients: clinicopathologic study of 176 cases. Arch Dermatol. 2003 Sep;139(9):1133-7.[Abstract]
41. Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011 Feb 1;154(3):190-201.[Abstract][Full Text]
42. Nasr I, McGrath EJ, Harwood CA, et al; British Association of Dermatologists' Clinical Standards Unit. British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021. Br J Dermatol. 2021 Nov;185(5):899-920.[Abstract][Full Text]
43. Marrett L, Rosen L, Zwaal C, et al; Cancer Care Ontario. Screening for skin cancer. Jun 2007 [internet publication].
44. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: basal cell skin cancer [internet publication].[Full Text]
45. Mogensen M, Jemec GB. Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies. Dermatol Surg. 2007 Oct;33(10):1158-74.[Abstract]
46. Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023 Oct;192:113254.[Abstract][Full Text]
47. Newlands C, Currie R, Memon A, et al. Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2):S125-32.[Abstract][Full Text]
48. Kim JYS, Kozlow JH, Mittal B, et al; Work Group, Invited Reviewers. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):540-59.[Abstract][Full Text]
49. Stulberg D, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinomas. Am Fam Physician. 2004 Oct 15;70(8):1481-8.[Abstract]
50. Balu M, Zachary CB, Harris RM, et al. In vivo multiphoton microscopy of basal cell carcinoma. JAMA Dermatol. 2015 Oct;151(10):1068-74.[Abstract][Full Text]
51. Foltz EA, Witkowski A, Becker AL, et al. Artificial Intelligence Applied to Non-Invasive Imaging Modalities in Identification of Nonmelanoma Skin Cancer: A Systematic Review. Cancers (Basel). 2024 Feb 1;16(3):629.[Abstract][Full Text]
52. Verzì AE, Russo A, Castellino N, et al. Line-field confocal optical coherence tomography of eyelid margin growths: A case series. Skin Res Technol. 2024 Jan;30(1):e13559.[Abstract][Full Text]
53. Smeets NW, Stavast-Kooy AJ, Krekels GA, et al. Adjuvant cytokeratin staining in Mohs micrographic surgery for basal cell carcinoma. Dermatol Surg. 2003 Apr;29(4):375-7.[Abstract]
54. Ackerman AB, Gottlieb GJ. Fibroepithelial tumor of pinkus is trichoblastic (Basal-cell) carcinoma. Am J Dermatopathol. 2005 Apr;27(2):155-9.[Abstract]
55. Helm KF, Cowen EW, Billingsley EM, et al. Trichoblastoma or trichoblastic carcinoma? J Am Acad Dermatol. 2001 Mar;44(3):547.[Abstract]
56. Massari LP, Kastelan M, Gruber F. Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis. Coll Antropol. 2007 Jan;31 Suppl 1:83-5.[Abstract]
57. Marek L, Grzanka A, Chmielowska E, et al. Merkel cell carcinoma: an illustrative case and review. Postepy Dermatol Alergol. 2014 Oct;31(5):325-8.[Abstract][Full Text]
58. US Preventive Services Task Force. Skin cancer: screening. Apr 2023 [internet publication].[Full Text]
59. Thomson J, Hogan S, Leonardi-Bee J, et al. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020 Nov 17;(11):CD003412.[Abstract][Full Text]
60. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012 Jun 7;366(23):2180-8.[Abstract]
61. Piccerillo A, Di Stefani A, Costantini A, et al. Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome and multiple basal cell carcinomas. Dermatol Ther. 2021 Sep;34(5):e15095.[Abstract]
62. Bogelund FS, Philipsen PA, Gniadecki R. Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol. 2007;87(4):330-4.[Abstract]
63. Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007 Aug;4(8):462-9.[Abstract]
64. Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Ann Intern Med. 2018 Oct 2;169(7):456-66.[Abstract][Full Text]
65. Wolf DJ, Zitelli JA. Surgical margins for basal cell carcinoma. Arch Dermatol. 1987 Mar;123(3):340-4.[Abstract]
66. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg. 1987 Jul;80(1):47-54.[Abstract]
67. Wang BC, Fu C, Qin L, et al. Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: a systematic review and meta-analysis. Photodiagnosis Photodyn Ther. 2020 Mar;29:101667.[Abstract]
68. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009 Dec;145(12):1431-8.[Abstract]
69. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgery versus imiquimod for nodular superficial basal cell carcinoma (SINS) study group. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):96-105.[Abstract][Full Text]
70. Williams HC, Bath-Hextall F, Ozolins M, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017 Mar;137(3):614-9.[Abstract][Full Text]
71. McKay KM, Sambrano BL, Fox PS, et al. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC. Br J Dermatol. 2013 Sep;169(3):549-54.[Abstract]
72. Neale H, Michelon M, Jacob S, et al. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: a retrospective cohort analysis. J Am Acad Dermatol. 2022 Aug;87(2):423-5.[Abstract][Full Text]
73. Jansen MHE, Mosterd K, Arits AHMM, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018 Mar;138(3):527-33.[Abstract][Full Text]
74. Cosgarea R, Susan M, Crisan M, et al. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013 Aug;27(8):980-4.[Abstract]
75. Wang H, Xu Y, Shi J, et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2015 Jan;31(1):44-53.[Abstract]
76. Collier NJ, Haylett AK, Wong TH, et al. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis. Br J Dermatol. 2018 Dec;179(6):1277-96.[Abstract]
77. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol. 2003 Dec;149(6):1242-9.[Abstract]
78. Christensen E, Mørk C, Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol. 2012 Jun;166(6):1342-8.[Abstract]
79. Osiecka B, Jurczyszyn K, Ziółkowski P. The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Med Sci Monit. 2012 Feb;18(2):PI5-9.[Abstract]
80. Garcia C, Poletti E, Crowson AN. Basosquamous carcinoma. J Am Acad Dermatol. 2009 Jan;60(1):137-43.[Abstract]
81. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989 Mar;15(3):315-28.[Abstract]
82. Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989 Apr;15(4):424-31.[Abstract]
83. Lear JT, Corner C, Dziewulski P, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014 Oct 14;111(8):1476-81.[Abstract][Full Text]
84. Bertrand N, Guerreschi P, Basset-Seguin N, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. EClinicalMedicine. 2021 May;35:100844.[Abstract][Full Text]
85. Hoashi T, Ishikawa M, Uehara J, et al. Japanese Dermatological Association guidelines: outlines of Japanese clinical guidelines for basal cell carcinoma 2021. J Dermatol. 24 Jan 2024 [Epub ahead of print].[Abstract][Full Text]
86. Kinj R, Gaide O, Jeanneret-Sozzi W, et al. Randomized phase II selection trial of FLASH and conventional radiotherapy for patients with localized cutaneous squamous cell carcinoma or basal cell carcinoma: a study protocol. Clin Transl Radiat Oncol. 2024 Mar;45:100743.[Abstract][Full Text]
87. Sekulic A, Migden MR, Basset-Seguin N, et al; ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16;17(1):332.[Abstract][Full Text]
88. Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017 Nov;86:334-48.[Abstract][Full Text]
89. Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-81.[Abstract][Full Text]
90. Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):848-57.[Abstract]
91. ClinicalTrials.gov. Study of patidegib topical gel, 2%, for the reduction of disease burden of persistently developing basal cell carcinomas (BCCs) in subjects with basal cell nevus syndrome (Gorlin syndrome). NCT03703310. Mar 2021 [internet publication].[Full Text]
92. ClinicalTrials.gov. Trial of patidegib gel 2%, 4%, and vehicle to decrease the number of surgically eligible basal cell carcinomas in Gorlin syndrome patients. NCT02762084. Jul 2020 [internet publication].[Full Text]
93. ClinicalTrials.gov. Clinical trial of patidegib gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). NCT02828111. Jan 2019 [internet publication].[Full Text]
94. Vidal D, Matias-Guiu X, Alomar A. Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up. Arch Dermatol. 2007 Feb;143(2):266-8.[Abstract]
95. Nagore E, Grau C, Molinero J, et al. Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. a retrospective study of 248 patients. J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70.[Abstract]
96. Weissferdt A, Kalhor N, Moran CA. Cutaneous basal cell carcinoma with distant metastasis to thorax and bone: a clinicopathological and immunohistochemical study of 15 cases. Virchows Arch. 2017 Jun;470(6):687-94.[Abstract]
97. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA. 1992 Jun 24;267(24):3305-10.[Abstract]
98. Flohil SC, van der Leest RJ, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. Eur J Cancer. 2013 Jul;49(10):2365-75.[Abstract]
99. Sánchez G, Nova J, Rodriguez-Hernandez AE, et al. Sun protection for preventing basal cell and squamous cell skin cancers. Cochrane Database Syst Rev. 2016 Jul 25;(7):CD011161.[Abstract][Full Text]
100. Berking C. Photocarcinogenesis: molecular mechanisms and preventive strategies. Hautarzt. 2007 May;58(5):398-405.[Abstract]
101. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med. 2015 Oct 22;373(17):1618-26.[Abstract][Full Text]
102. Schauder DM, Kim J, Nijhawan RI. Evaluation of the use of capecitabine for the treatment and prevention of actinic keratoses, squamous cell carcinoma, and basal cell carcinoma: a systematic review. JAMA Dermatol. 2020 Oct 1;156(10):1117-24.[Abstract]